<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE310nnn/GSE310689/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310689</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming in prostate cancer [RNA-Seq]</name><description>The polymorphic CAG trinucleotide repeat in the androgen receptor (AR) gene encodes a variable-length N-terminal polyglutamine (polyQ) tract that modulates AR transcriptional activity, with shorter tracts generally enhancing AR activity. While the majority of men harbor CAG repeats longer than 17, a small subset carry minimal-length CAG repeats (≤17) in AR. These alleles are primarily found in men of African ancestry (AA), accounting for over 10% of the population, and may significantly contribute to the increased prostate cancer (PCa) risk and worse clinical outcomes observed in AA men. However, how this distinct pattern of polymorphism influences AR-chromatin interaction, metabolic reprogramming, and therapeutic response remains unclear. Here, we established isogenic PCa cell lines harboring AR with a minimal length of CAG repeats that encode an ultrashort polyQ track and found that this AR variant exhibits resistance to AR-targeted therapy with markedly enhanced protein stability, expanded chromatin binding, and a reprogrammed transcriptional profile. Notably, the ultrashort polyQ AR also reshaped global FOXA1 occupancy and upregulated genes involved in fatty acid metabolism, lipid synthesis, and anaerobic glycolysis. Moreover, we identified a markedly increased AR-LSD1 interaction and showed that LSD1 inhibition suppressed this metabolic reprogramming and reduced tumor growth. Together, these findings define a hyperactive AR-LSD1 chromatin axis driven by minimal-length CAG repeats in AR and reveal a mechanistic link between inherited AR polymorphism, AR-mediated epigenetic–metabolic remodeling, and population-associated disparities in prostate cancer biology.</description><dates><publication>2026/08/28</publication></dates><accession>GSE310689</accession><cross_references><GSM>GSM9306919</GSM><GSM>GSM9306921</GSM><GSM>GSM9306920</GSM><GSM>GSM9306923</GSM><GSM>GSM9306922</GSM><GSM>GSM9306925</GSM><GSM>GSM9306924</GSM><GSM>GSM9306927</GSM><GSM>GSM9306926</GSM><GSM>GSM9306918</GSM><GSM>GSM9306929</GSM><GSM>GSM9306928</GSM><GPL>30173</GPL><GSE>310689</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>